digoxin / Generic mfg. - LARVOL DELTA

Xinmailong Injection Attenuates Doxorubicin-Induced Chronic Heart Failure by Regulating the SIRT1/Caspase-3 Axis and Metabolic Reprogramming: An Integrative Network Pharmacology and Metabolomics Study. (PubMed, Curr Med Sci) - "XML ameliorates doxorubicin-induced CHF via improving cardiac function, mitigating myocardial injury/fibrosis, restoring metabolic homeostasis and inhibiting cardiomyocyte apoptosis, which is closely related to regulating the SIRT1/caspase-3 axis and multiple metabolic pathways."

IO biomarker • Journal • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Heart Failure • Immunology • Lymphoma • Metabolic Disorders • Myocardial Infarction • Oncology • BAX • CASP3

Performance of large language models on narrow therapeutic index drug monitoring: Implications for clinical pharmacy practice. (PubMed, J Am Pharm Assoc (2003)) - "The evaluated LLMs performed strongly in recognizing TDM problems in structured vignettes but showed variability in reasoning-intensive tasks, with overconfident reasoning representing a potential patient safety concern. Pharmacist oversight remains essential for TDM tasks."

Journal

Heart Failure Pharmacotherapy and Long-Term Outcomes After Extracorporeal Membrane Oxygenation: A Nationwide Real-World Cohort Study. (PubMed, Int J Gen Med) - "Use shifted from angiotensin-converting enzyme inhibitors and digoxin toward angiotensin receptor blockers, beta-blockers, sodium-glucose cotransporter 2 inhibitors, and ivabradine. Among 6-month survivors of cardiogenic ECMO, a high-risk and clinically unique population often excluded from HF trials, post-discharge HF pharmacotherapy was associated with lower long-term mortality. These findings support structured cardiovascular reassessment and individualized HF medication review after ECMO."

Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

DIGOXIN VS AMIODARONE IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE WITH REDUCED EJECTION FRACTION NOT UNDERGOING CATHETER ABLATION: A MULTICENTER STUDY (CHEST 2026) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

NO WAY OUT: REBOUND DIGOXIN TOXICITY IN END-STAGE RENAL DISEASE (CHEST 2026) - No abstract available

Nephrology • Renal Disease

Digoxin Toxicity (CHEST 2026) - No abstract available

Thyroid Storm Presenting With Refractory Atrial Arrhythmia and Tachycardia-Induced Dilated Cardiomyopathy: A Case Report. (PubMed, Cureus) - "Multiple rhythm-control and rate-control strategies were required, including direct-current cardioversion, adenosine, magnesium, digoxin, beta-blockers and escalating infusions. Amiodarone was discontinued following multidisciplinary review due to concerns regarding iodine-induced exacerbation of thyrotoxicosis. Thyroid storm was treated with propylthiouracil, Lugol's iodine, hydrocortisone, propranolol and cholestyramine. Serial echocardiography demonstrated interval improvement in left ventricular systolic function, supporting a reversible tachycardia-mediated mechanism. This case highlights the diagnostic and therapeutic complexity of thyroid storm with refractory arrhythmia and underscores the importance of early recognition, multidisciplinary management and careful selection of antiarrhythmic therapy."

Journal • Cardiomyopathy • Cardiovascular • Cognitive Disorders • Congestive Heart Failure • Endocrine Disorders • Grave’s Disease • Heart Failure • Hypertension • Metabolic Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Efficacy and safety of digoxin/furosemide for cutaneous warts: a systematic review and meta-analysis of eight randomized controlled trials. (PubMed, Ann Med Surg (Lond)) - "However, due to the low to very low certainty of the current evidence, these findings are preliminary. Further robust, large-scale RCTs are required to confirm its clinical utility and definitively establish its role in standard practice."

Journal • Retrospective data • Dermatology • Hematological Disorders • Oncology

Prescription Patterns of Cardiovascular Medications in the Adolescent and Adult Population With Fontan Circulation-A Report From the Multicenter Single Ventricle Outcomes Network. (PubMed, J Am Heart Assoc) - "In a multicenter cohort of adolescents and adults with Fontan circulation, medications indicated for biventricular heart failure with reduced ejection fraction are often used despite an absence of supportive evidence in this distinct circulation. Future prospective analysis may provide further insight into shifting prescribing patterns and response to therapy."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Transplantation

Low-Dose Digoxin Ameliorates Age-Related Motor Learning Deficits in Mice. (PubMed, Neurochem Res) - "Furthermore, agrin-derived fragments have been reported to interact with Na/K ATPase, suggesting that this fragment may function as a molecular interface between extracellular signaling and synaptic structural remodeling. Together, these results indicate that modulation of Na/K ATPase activity enhances motor learning and dendritic spine remodeling in the aged motor cortex through mechanisms that do not require increased BDNF protein levels."

Journal • Preclinical

Early Digoxin Therapy After Lvad Implantation: Insights From A Us-based Multicenter Retrospective Cohort. [Poster no. 243] (HFSA 2026) - No abstract available

Retrospective data

Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial. (PubMed, Nat Med) - P1 | "Thus, our data provide a first-in-human proof of principle that digoxin treatment leads to a partial CTC cluster dissolution, encouraging larger follow-up studies with refined Na+/K+ ATPase inhibitors and that include clinical outcome endpoints. ClinicalTrials.gov identifier: NCT03928210 ."

Circulating tumor cells • Journal • Breast Cancer • Oncology • Solid Tumor

Digoxin Toxicity in Anthracycline-Induced Cardiomyopathy Despite Normal Renal Function A Case Report (AHA 2026) - "Abstract is embargoed at this time."

Case report • Clinical • Cardiomyopathy • Cardiovascular

Digoxin for Symptomatic Rheumatic Heart Disease-Reply. (PubMed, JAMA) - No abstract available

Journal • Cardiovascular • Heart Failure

Digoxin for Symptomatic Rheumatic Heart Disease. (PubMed, JAMA) - No abstract available

Journal • Cardiovascular • Heart Failure

Digoxin for Symptomatic Rheumatic Heart Disease. (PubMed, JAMA) - No abstract available

Journal • Cardiovascular • Heart Failure

A SHAP-Informed Formal Feature Attribution Framework for Drug-Drug Interaction Risk in Large-Scale Claims Data. (PubMed, Clin Transl Sci) - "FFA flagged 115 synergistic pairs and 312 high-confidence triplets (e.g., furosemide + hydrochlorothiazide + lisinopril; digoxin + furosemide + amiodarone, IE = 8.7). Top Intervention Rate drugs included simvastatin, furosemide, and alprazolam. Moderate preventive Z-code monitoring (Q2) was protective (OR = 0.25; 95% CI 0.18-0.34) versus no monitoring, while fragmented high-intensity monitoring (Q4) was not. The framework prioritizes medication combinations for pharmacist review in claims data; it does not replace pharmacokinetic confirmation or prove that changing a drug caused fewer ED visits."

Journal

Evaluation of digoxin dosing and therapeutic drug monitoring in adult patients receiving continuous venovenous hemodiafiltration. (PubMed, Ther Adv Drug Saf) - "Two patients (33.3%) experienced bradycardia, both of whom were receiving concomitant amiodarone. These data help address the current gap in data describing digoxin dosing during CRRT. Although this adds limited insight for digoxin dosing during CRRT, standard dosing and monitoring recommendations remain unconfirmed."

Journal • Cardiovascular • Critical care

Longer-term prognostic benefit of low-dose digoxin versus beta-blockers in patients with permanent atrial fibrillation and symptoms of heart failure (ESC 2026) - No abstract available

Clinical • Late-breaking abstract • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Low-dose Digoxin in Women and Men with Heart Failure: Data from DECISION (ESC 2026) - No abstract available

Clinical • Late-breaking abstract • Cardiovascular • Congestive Heart Failure • Heart Failure

Early or late, benefits of digoxin reconsidered in HFrEF: Insights from the Digitalis Investigation Group Trial (DIG) (ESC 2026) - No abstract available

Late-breaking abstract • Cardiovascular • Congestive Heart Failure • Heart Failure

A mechanistic evaluation of sodium channel modulators in hiPSC-derived cardiomyocytes using fluorescence-based sodium flux imaging. (PubMed, Biotechnol Lett) - "Our results demonstrate that Nav1.5 activators (e.g., Aconitine) and Na+/K+-ATPase inhibitors (e.g., Ouabain, Digoxin) significantly increase intracellular Na+ levels at both 1-h and 24-h intervals. This imaging-based approach provides a mechanistic tool for distinguishing sodium channel modulators, offering an alternative for next-generation cardiovascular safety pharmacology."

Journal • Cardiovascular • ATP1A1 • NAV1 • SLC8A1

Safety of Intra-Amniotic and Intra-Fetal Digoxin Administration in Late Second-Trimester Abortion by Dilation and Evacuation. (PubMed, Perspect Sex Reprod Health) - "Neither 1.5 mg IAI nor 1.0 mg IFI of digoxin administered to induce fetal demise was associated with adverse maternal cardiac outcomes or coagulation parameter changes. Serum levels reflected significant digoxin absorption in both groups, generally resulting in maximum digoxin concentration peaks in the low therapeutic range. Injecting digoxin to cause fetal demise in abortion care appears safe and effective."

Journal

Does evidence-based treatment recommendations implementation improve 1-year outcomes in patients with heart failure? (ESC 2026) - "In terms of treatment, there was a significant reduction in the use of diuretics, digoxin, ivabradine and ACEI/ARB, and a very significant increase in ARNI, MRA, SGLT2 inhibitors and potassium chelators (Figure 1). In our contemporary cohort of real-life HF patients, the use of ARNI, SGLT2 inhibitors and MRAs increased very markedly from 2019 to 2024, reflecting a rapid implementation of clinical practice guideline recommendations. However, this was not associated with a reduction in mortality or HF decompensations, despite a lower severity profile of HF in the most recent period. The reasons for this discrepancy should be carefully analyzed."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

Digoxin initiation in advanced heart failure with reduced ejection fraction and atrial fibrillation: a nationwide target trial emulation study (ESC 2026) - "Digoxin initiation was associated with a lower risk of CVD/HHF and ACD/HHF, mainly driven by HHF, in severely symptomatic patients with HFrEF and AF. Patients with baseline heart rates between 75 and 110 bpm had the greatest benefit from digoxin initiation."

Metastases • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure